Adagene Inc. ADAG
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +32.80%
- 1 year
- +30.73%
- Open
- 2.67
- Prev close
- 2.68
- Mkt cap
- 168.53M
- Vol
- 79.69K
- Avg vol
- 279.93K
- EPS
- -0.38
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.46
- High
- 2.69
- Forward P/E
- -2.81
- Beta
- 0.58
- Short ratio
- 0.66
- Inst. own
- 25.20%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 2, 2024
- 50-d avg
- 2.44
- 200-d avg
- 2.59
- 1y target
- 8.03
News
-
5 days ago benzinga.com
Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
5 days ago globenewswire.com
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte's TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
6 days ago globenewswire.com
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…
1 week ago marketbeat.com
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer
Adagene NASDAQ: ADAG is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant…
2 weeks ago defenseworld.net
Adagene (NASDAQ:ADAG) Stock Rating Reaffirmed as “Buy” by HC Wainwright
Adagene (NASDAQ: ADAG - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday, MarketBeat.com reports. They presently…
2 weeks ago defenseworld.net
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
Adagene (NASDAQ: ADAG) Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development…
2 weeks ago marketbeat.com
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts
Adagene NASDAQ: ADAG Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development milestones…
2 weeks ago globenewswire.com
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel…
-
1 month ago benzinga.com
China’s NMPA Approves Adagene’s IND Application For ADG138, Double-Masked HER2×CD3 Bispecific T Cell Engager Built On Proprietary SAFEbody Precision Masking Technology
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026ADG138 is a double-masked T-cell engager, applying Adagene’s proprietary…
1 month ago globenewswire.com
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene's proprietary…
1 month ago defenseworld.net
Insider Buying: Adagene (NASDAQ:ADAG) CEO Acquires $63,913.50 in Stock
Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) CEO Peter Luo acquired 20,290 shares of the business's stock in a transaction dated Wednesday, September 16th. The shares were acquired at…
1 month ago seekingalpha.com
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that…
1 month ago globenewswire.com
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.
-
1 month ago benzinga.com
Chardan Capital Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Chardan Capital analyst Gautam Chukka initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
1 month ago globenewswire.com
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…
2 months ago globenewswire.com
Adagene to Participate in Three Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel…
-
2 months ago benzinga.com
Adagene H1 Adj. EPS $(0.20) Misses $(0.10) Estimate, Sales $1.620M
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.10) by 100 percent. This is a 5.26 percent decrease over losses of $(0.19) per…
2 months ago globenewswire.com
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen…
4 months ago zacks.com
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
5 months ago zacks.com
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
5 months ago marketbeat.com
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst…
5 months ago globenewswire.com
Adagene to Participate in Two Upcoming Investor Conferences
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based…
6 months ago defenseworld.net
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Growth in Short Interest
Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling…
-
6 months ago benzinga.com
Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%,…
6 months ago globenewswire.com
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%,…
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
Guggenheim Maintains Buy on Adagene, Raises Price Target to $10
Guggenheim analyst Paul Jeng maintains Adagene (NASDAQ:ADAG) with a Buy and raises the price target from $9 to $10.
-
7 months ago benzinga.com
Adagene Announces Results From Latest Data Cut From Phase 1b/2 Study Of Muzastotug In Patients With Advanced Microsatellite Stable Colorectal Cancer With No Liver Metastases
Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement…
-
7 months ago benzinga.com
Adagene Collaborates With Incyte To Evaluate Combination Of Muzastotug And INCA33890 In Patients With Microsatellite Stable Colorectal Cancer With Or Without Liver Metastases
Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metastasesStudy will be sponsored and conducted by Incyte; Adagene to provide…
-
7 months ago benzinga.com
Adagene FY Adj. EPS $(0.24) Misses $(0.15) Estimate, Sales $7.671M Beat $1.667M Estimate
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.15) by 60 percent. This is a 52.94 percent increase over losses of $(0.51) per…
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
9 months ago benzinga.com
Adagene Announces Data Update From Ongoing Phase 1b/2 Study Of Muzastotug + Pembrolizumab In 3L+ MSS CRC Patients Remains On Track For Q1 2026
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash and cash equivalents of $74.5 million as of December 31,…
-
11 months ago benzinga.com
Guggenheim Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Guggenheim analyst Paul Jeng initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
11 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
Adagene Says First Patient Dosed In Randomized, Open Label Phase 2 Study Of Muzastotug In Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA In Patients With MSS CRC With No Liver Metastases
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDAPatients randomized to either 10 or 20 mg/kg of muzastotug,…
-
1 year ago benzinga.com
LUCID CAPITAL MARKETS Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
LUCID CAPITAL MARKETS analyst Christopher Liu initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
HC Wainwright & Co. Maintains Buy on Adagene, Lowers Price Target to $7
HC Wainwright & Co. analyst Arthur He maintains Adagene (NASDAQ:ADAG) with a Buy and lowers the price target from $8 to $7.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
Adagene H1 Adj. EPS $(0.19) Beats $(0.34) Estimate
Adagene (NASDAQ:ADAG) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 26.92 percent increase over losses of $(0.26) per…
1 year ago benzinga.com
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
-
1 year ago benzinga.com
Leerink Partners Initiates Coverage On Adagene with Outperform Rating, Announces Price Target of $7
Leerink Partners analyst Daina Graybosch initiates coverage on Adagene (NASDAQ:ADAG) with a Outperform rating and announces Price Target of $7.
-
1 year ago benzinga.com
Sanofi Invests Up to $25M in Adagene to Advance Cancer Drug Trials
Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise…
-
2 years ago benzinga.com
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
2 years ago benzinga.com
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode…
-
2 years ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session